A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
This clinical trial is testing a new study drug called FOG-001 to see if it is safe and effective for people with advanced solid tumor cancers or a specific inherited condition called familial adenomatous polyposis. Researchers want to find the best dose of this investigational medicine to help patients whose cancer has not responded to standard treatments.
You may be eligible if you have an advanced or spreading solid tumor that has stopped responding to other treatments, and you are generally able to carry out your daily activities. Your vital organs and bone marrow must be working well, and you must not have certain conditions like uncontrolled heart problems or active digestive tract inflammation.
Participants will receive the investigational study drug FOG-001, and doctors will carefully monitor your health and safety throughout the process. You will also need to have at least one tumor area that is safe for doctors to take a small tissue sample using a needle.
This study is currently recruiting participants and takes place at multiple locations in Phoenix, Scottsdale, and Tucson, Arizona. Your study doctor can provide more specific details about the exact clinic locations.
- 1Testing a new investigational drug called FOG-001 for advanced solid tumors
- 2Currently recruiting patients at several locations in Arizona
- 3Requires participants to have tumors where tissue samples can be safely taken
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.